29 research outputs found

    A METHOD OF ANALYSIS IN THE SOLAR OCCULTATION MEASUREMENTS

    Get PDF
    1983-03-25On the basis of the solar occultation method we measured in recent years the densities of aerosol and ozone in the lower stratosphere by balloon-borne sun-photometers. In reducing the observed optical depth to the extinction profile we have improved analytical procedures. It is essential in the procedures to estimate as accurately as possible the effect of refraction and absorption of sunlight in the atmosphere. This report describes a practical technique which is commonly applicable to the analysis of solar occultation measurements.departmental bulletin pape

    Close correlation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate, an intracellular active metabolite, to the therapeutic efficacy of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine therapy for acute myelogenous leukemia.

    Get PDF
    N(4)-Behenoyl-1-beta-D-arabinofuranosylcytosine (BHAC), a prodrug of 1-beta-D-arabinofuranosylcytosine, is used effectively for the treatment of leukemia in Japan. BHAC therapy may be more effective if it is delivered in conjunction with monitoring of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP), the intracellular active metabolite of ara-C derived from BHAC. However, previous monitoring methods for ara-CTP were insufficiently sensitive. Here, using our new sensitive method, we evaluated the ara-CTP pharmacokinetics in relation to the therapeutic response in 11 acute myelogenous leukemia patients who received a 2-h infusion of BHAC (70 mg / m(2)) in combination remission induction therapy. ara-CTP could be monitored at levels under 1 mM. BHAC maintained effective levels of plasma ara-C and intracellular ara-CTP for a longer time, even compared with historical values of high-dose ara-C. The area under the concentration-time curve of ara-CTP was significantly greater in the patients with complete remission than in the patients without response. This greater amount of ara-CTP was attributed to the higher ara-CTP concentrations achieved in the responding patients. There was no apparent difference of plasma ara-C pharmacokinetics between the two groups. Thus, for the first time, the ara-CTP pharmacokinetics was evaluated in relation to the therapeutic effect of BHAC, and the importance of ara-CTP was proven. Administration of optimal BHAC therapy may require monitoring of the ara-CTP pharmacokinetics in each individual patient.othe

    佐藤政権期における対ビルマ経済協力 : 対ビルマ円借款の起点

    No full text
    departmental bulletin pape

    Quantification of fragile telomeres in wild-type and <i>Nth1<sup>−/−</sup></i> mouse bone marrow cells and primary MEFs treated with a low dose of aphidicolin.

    No full text
    <p>Values indicate percentage of fragile telomeres. Bone marrow cells (6 mice) and MEFs (4 lines) are treated with aphidicolin for 16 hours. At least 50 metaphases are counted.</p>*<p>denotes P-values that yield significant difference compared with wild type (untreated).</p

    Detection of oxidative DNA base lesions at telomeres in mice.

    No full text
    <p>Genomic DNA is detected for Endonuclease III-sensitive DNA lesions per kilobase of telomeric DNA by a modified quantitative telomere PCR method. (A) Endonuclease III-sensitive DNA lesions in wild-type and <i>Nth1<sup>−/−</sup></i> mouse kidney (n = 6 mice). (B) Endonuclease III-sensitive DNA lesions in primary MEFs (untreated) or MEFs exposed to 5 µM Benzo(a)pyrene for 24 hours followed by recovery for 0 hour or 8 hours. Each sample is analyzed in triplicate. Error bars denote standard deviation. P-values are calculated using a Student's <i>t</i>-test and adjusted using Benjamini-Hochberg False Discovery Rate-controlling method <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1003639#pgen.1003639-Benjamini1" target="_blank">[57]</a>. P-values<0.05 are statistically significant using the above method.</p

    Fragile telomeres in wild-type and <i>Nth1<sup>−/−</sup></i> mouse cells.

    No full text
    <p>(A) Examples of fragile telomeres by telomere-FISH analysis. (B–D) Percentage of fragile telomeres in primary MEFs (4 MEF lineages), freshly isolated bone marrow cells (11 mice), and bone marrow cells that are stimulated in culture (10 mice). At least 60 metaphases/sample are counted. Error bars indicate standard deviation. P-values are calculated using a Student's <i>t</i>-test.</p

    DNA damage foci in wild-type and <i>Nth1<sup>−/−</sup></i> primary MEFs.

    No full text
    <p>53BP1 foci at genome or telomeres are detected by IF and IF-telomere FISH, respectively. (A) Percentage of wild-type and <i>Nth1<sup>−/−</sup></i> cells with various numbers of 53BP1 foci in the genome. (B) Percentage of wild-type and <i>Nth1<sup>−/−</sup></i> cells with greater than or equal to three 53BP1 foci that colocalize with telomere DNA. APH: cells treated with 0.2 uM aphidicolin for 16 hours. (C) A representative <i>Nth1<sup>−/−</sup></i> cell showing telomeric DNA (red) and 53BP1 foci (green). N = 4 mice, at least 100 cells/sample are counted. Error bars indicate standard deviation. P-values are calculated using a Student's <i>t</i>-test and adjusted using Benjamini-Hochberg False Discovery Rate -controlling method. P-values<0.05 are statistically significant using the above method.</p

    Telomere length and DNA damage foci in <i>Nth1<sup>+/+</sup>Tert<sup>−/−</sup></i> and <i>Nth1<sup>−/−</sup>Tert<sup>−/−</sup></i> mouse cells.

    No full text
    <p>(A) Q-FISH analysis of bone marrow cells derived from <i>Nth1<sup>+/+</sup> Tert<sup>−/−</sup></i> and <i>Nth1<sup>−/−</sup>Tert<sup>−/−</sup></i> mice (n = 8). Representative quantitative measurement of telomere signal intensity is shown in jitter plot displaying complete distribution of telomeres with diverse signal intensity (left panel) and in a combined histogram displaying relative frequency of telomeres plotted against telomere signal intensity (right panel). Bars (in green) denote mean telomere signal intensity. (B) Representative metaphase spreads from indicated genotypes, showing enlarged chromosome ends with or without telomere signals (Normal and SFE, respectively). Arrows depict SFEs. (C) Quantification of SFEs in bone marrow cells with indicated genotypes (8 mice). At least 50 metaphases/sample are counted. Values depict mean values ± SD from each sample. P-values are calculated using a Student's <i>t</i>-test. * represents P = 0.01. (D–E) Percentage of <i>Nth1<sup>+/+</sup> Tert<sup>−/−</sup></i> and <i>Nth1<sup>−/−</sup>Tert<sup>−/−</sup></i> cells with various numbers of γ-H2AX foci in the genome and telomeres by IF and IF-telomere FISH analysis, respectively. At least 100 cells/sample are counted. Error bars indicate standard deviation.</p
    corecore